ARCHIVES

FDA Hears More Criticism On Cancer Drug Endpoints; Joint Conferences On Criteria Recommended

This article is from The Cancer Letter archive.

Vol. 15 No. 30 | July 28, 1989

Download PDF Visit The Full Archive

Related Articles

Guest Editorial By ACS Chief Medical Officer Otis Brawley: ACS Revises Process for Making Guidelines

January 13, 2012

NCI Advisory Group, Other Cancer Meetings

January 2, 1981

NCI Receives 165 SBIR Grant Applications; Combines With Solid Contracts, No More Fiascos Are Expected

June 14, 1985

Draft Report Outlines New Toxicological Test Criteria

November 24, 1995

In Brief: David Chambers named deputy director for implementation science at NCI DCCPS

December 5, 2014

NCI Urged To Back Ultrasounds Studies

October 1, 1976